

Nepal Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Nepal							
2. Grant number(s): 1821-NPL-04c-X; 08-NPL-08b-Y							
3. Date of Decision Letter: 27 March 2019							
4. Date of the Partnership Framework Agreement: 22 August 2014							
5. Programme title: New Vaccine Support (NVS), Pentavalent Routine							
6. Vaccine type: Pentavalent							
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 dose(s) per vial, LIQUID							
8. Programme duration¹: 2009 -2021							
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)							
	2009-2018	2019	2020	2021	Total ²		
Programme Budget (US\$)	37,557,014 ³	1,391,500	1,207,500	1,138,500	41,294,514		
10. Vaccine introduction grant (in US\$)							
<table border="1" style="margin-left: auto; margin-right: auto;"> <tr> <td style="text-align: center;">2008</td> </tr> <tr> <td style="text-align: center;">266,500 disbursed on 7 August 2008</td> </tr> </table>						2008	266,500 disbursed on 7 August 2008
2008							
266,500 disbursed on 7 August 2008							
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁴							
Type of supplies to be purchased with Gavi funds in each year	2009-2018	2019					
Number of Pentavalent vaccines doses		1,955,500					
Annual Amounts (US\$)	37,557,014 ⁵	1,391,500					
12. Procurement agency: UNICEF Country shall release its co-financing payments each year to UNICEF.							
13. Self-procurement: Not applicable							

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<p>14. Co-financing obligations: Reference code: 1821-NPL-04c-X-C</p> <p>According to the co-financing policy, Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>									
Type of supplies to be purchased with Country funds in each year	2019	2020	2021						
Number of vaccine doses	765,500	664,000	626,000						
Value of vaccine doses (US\$)	527,873	458,033	431,843						
Total co-financing payments (US\$) (including freight)	544,500	472,500	445,500						
<p>15. Operational support for campaigns: Not applicable</p>									
<p>16. Additional reporting requirements:</p> <table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td> <p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td> <p>31 March 2019</p> <p>15 May 2019</p> </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>				Reports and other information	Due dates	<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 2019</p> <p>15 May 2019</p>	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
Reports and other information	Due dates								
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 2019</p> <p>15 May 2019</p>								
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat								
<p>17. Financial clarifications: Not applicable</p>									
<p>18. Other conditions: Not applicable</p>									

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
27 March 2019